Journal of Clinical Oncology, Vol 1, 727-740, Copyright © 1983 by American Society of Clinical Oncology
Treatment of the carcinoid tumor and the malignant carcinoid syndrome
CG Moertel
Certainly in treatment of the carcinoid tumor surgery has a well-
established curative and palliative potential. The primary challenge is a
knowledgable marriage between stage of disease and aggressiveness of
operative procedure. Nonsurgical treatment of the malignant disease per se
has thus far not produced optimum results and, in the opinion of this
author, should still be confined to a clinical research setting. It would
seem very doubtful, however, that the more mundane types of trials,
empirically testing drug after drug and arbitrarily concocted drug
combinations, is the most productive road to follow. There is an evident
need for more sophisticated approaches to this tumor, which has unique
metabolic characteristics that should be pharmacologically exploitable.
Past experience has indicated that such a setting may permit dramatic
therapeutic accomplishment. There is a strong need for animal models or
established cell lines which would facilitate preclinical therapeutic
exploration. The carcinoid syndrome presents an unparalleled opportunity
for fundamental physiologic observations and for experimental therapeutic
study that can have applicability not only in palliating the syndrome
itself but also in the management of other pathophysiologic states that may
involve more subtle abnormalities of the same hormonal mechanisms. The
patient with the carcinoid tumor should not just be a fascinating curio for
grand rounds exhibition. He should be a focal point for research involving
an experienced, multidisciplinary clinical team supported by devoted basic
scientists. If our patient resources and efforts can be concentrated in
this manner, the carcinoid should be a strong candidate for the next
medically curable human cancer.
This article has been cited by other articles:

|
 |

|
 |
 
D. G. Haller
The Next 25 Years
J. Clin. Oncol.,
December 20, 2008;
26(36):
5840 - 5840.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. K. Kvols
Revisiting C.G. Moertel's Land of Small Tumors
J. Clin. Oncol.,
November 1, 2008;
26(31):
5005 - 5007.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Van Buren II, A. Rashid, A. D. Yang, E. K. Abdalla, M. J. Gray, W. Liu, R. Somcio, F. Fan, E. R. Camp, J. C. Yao, et al.
The Development and Characterization of a Human Midgut Carcinoid Cell Line
Clin. Cancer Res.,
August 15, 2007;
13(16):
4704 - 4712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Van Gompel, M. Kunnimalaiyaan, K. Holen, and H. Chen
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells
Mol. Cancer Ther.,
June 1, 2005;
4(6):
910 - 917.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Kwekkeboom, J. J. Teunissen, W. H. Bakker, P. P. Kooij, W. W. de Herder, R. A. Feelders, C. H. van Eijck, J.-P. Esser, B. L. Kam, and E. P. Krenning
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
J. Clin. Oncol.,
April 20, 2005;
23(12):
2754 - 2762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Kaltsas, G. M. Besser, and A. B. Grossman
The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
Endocr. Rev.,
June 1, 2004;
25(3):
458 - 511.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Connolly, H. V. Schaff, C. J. Mullany, M. D. Abel, and P. A. Pellikka
Carcinoid Heart Disease: Impact of Pulmonary Valve Replacement in Right Ventricular Function and Remodeling
Circulation,
September 24, 2002;
106(12_suppl_1):
I-51 - I-56.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Connolly, H. V. Schaff, C. J. Mullany, J. Rubin, M. D. Abel, and P. A. Pellikka
Surgical Management of Left-Sided Carcinoid Heart Disease
Circulation,
September 18, 2001;
104(90001):
I-36 - 40.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Gilbert, L. M. Frederick, and M. M. Ames
The Aromatic-L-Amino Acid Decarboxylase Inhibitor Carbidopa Is Selectively Cytotoxic to Human Pulmonary Carcinoid and Small Cell Lung Carcinoma Cells
Clin. Cancer Res.,
November 1, 2000;
6(11):
4365 - 4372.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Öberg
Carcinoid Tumors: Current Concepts in Diagnosis and Treatment
Oncologist,
October 1, 1998;
3(5):
339 - 345.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
O. Laccourreye, D. Brasnu, F. Carnot, P. Fichaux, and H. Laccourreye
Carcinoid (Neuroendocrine) Tumor of the Arytenoid
Arch Otolaryngol Head Neck Surg,
December 1, 1991;
117(12):
1395 - 1399.
[Abstract]
[PDF]
|
 |
|
|